Alkermes plc (ALKS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 | 1,668 | 1,822 |
| Operating profit | $m | 254 | 117 | ||||||
| Net profit | $m | -111 | -48 | -158 | 356 | 367 | 242 | 66 | -83 |
| EPS reported | $ | 1.43 | 0.38 | ||||||
| Operating cashflow per share | $ | 3.16 | 1.51 | ||||||
| Capex per share | $ | 0.25 | 0.18 | ||||||
| FCF per share | $ | 2.92 | 1.33 | ||||||
| Free cash flow | $m | 480 | 222 | ||||||
| Net debt | $m | -1,313 | 847 | ||||||
| Book value equity | $m | 1,819 | 1,809 | ||||||
| Book value per share | $ | 10.78 | 10.85 | ||||||
| Number of shares | m | 168.74 | 166.61 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.57 | 106.66 | ||||||
| P/B LTM | x | 2.53 | 2.55 | ||||||
| P/S LTM | x | 3.12 | 2.76 | ||||||
| P/FCF LTM | x | 9.59 | 20.79 | ||||||
| EV/EBITDA LTM | x | 10.75 | 16.32 | ||||||
| EV/Sales LTM | x | 2.41 | 5.27 | ||||||
| Earnings Yield LTM | % | +5.11% | +0.94% | ||||||
| FCF Yield | % | +10.42% | +4.81% | ||||||
| Quality | |||||||||
| ROE | % | +13.28% | +3.72% | ||||||
| ROIC | % | +10.56% | +2.12% | ||||||
| Operating margin | % | +17.21% | +7.03% | ||||||
| Gross margin | % | +86.69% | +84.56% | ||||||
| FCF/Sales | % | +32.55% | +13.29% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -34.10% | -82.49% | ||||||
| Sales Growth YoY | % | -5.25% | +7.06% | ||||||
| Net Income Growth YoY | % | -34.16% | -81.99% | ||||||
| FCF Growth | % | +18.41% | -45.36% | ||||||
| Operating Profit Growth | % | -39.63% | -72.12% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 6.86 | 0.14 | ||||||
| Net Debt/EBITDA | x | -3.17 | 4.87 | ||||||
| EBIT/Net interest | x | 20.69 | 1.98 | ||||||
| Net debt/market cap | % | +0.15% | +19.44% | ||||||
| Net debt/Equity | x | -0.72 | 0.47 | ||||||
| Gross debt/equity | x | 0.04 | 0.87 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free